Definium Therapeutics, Inc. Common Shares
$38.81
$0.13 (+0.34%)
$38.10Day Range$39.04
Key Statistics
Market Cap
$5.21B
Shares Outstanding
134.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 3, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$38.67
Day High
$39.04
Day Low
$38.10
Volume
3.22M
VWAP
$38.69
Prev Close
$38.68
Transactions
--
Acc. Volume
--
About Definium Therapeutics, Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
MEDICINAL CHEMICALS & BOTANICAL PRODUCTSSIC 2833106 employeesONE WORLD TRADE CENTER, NEW YORK, NY, 10007212-220-6633IPO Mar 3, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001813814
- Composite FIGI
- BBG00F13HYQ7
- Share Class FIGI
- BBG001TCSL84
- Ticker Root
- DFTX
- SIC Code
- 2833
About Definium Therapeutics, Inc. Common Shares (DFTX) Stock
Definium Therapeutics, Inc. Common Shares (DFTX) closed the 2026-09-18 session at $38.81, up 0.34% versus the previous close (+0.13). The stock opened at $38.67 and traded between $38.10 and $39.04 during that session. Session trading volume was 3.2M shares. The volume-weighted average price (VWAP) is $38.69.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Definium Therapeutics, Inc. Common Shares has a market capitalization of $5.21 billion. The company operates in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry classification. DFTX is listed on the XNAS exchange. The company employs approximately 106 people. Definium Therapeutics, Inc. Common Shares is headquartered in NEW YORK, NY. The recorded listing date is 2020-03-03.
On this page you can find market DFTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector.